Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $409.1M | $556.7M | $668.9M | $642.3M | $925.3M | $1.10B | $1.27B | $1.30B |
| Cost of revenue | $77.2M | $101.7M | $134.1M | $129.2M | $177.8M | $223.4M | $271.5M | $322.3M |
| Gross profit | $332.0M | $455.0M | $534.8M | $513.1M | $747.5M | $873.9M | $995.6M | $981.4M |
| Gross margin | 81.1% | 81.7% | 80.0% | 79.9% | 80.8% | 79.6% | 78.6% | 75.3% |
| R&D | $62.2M | $115.2M | $141.1M | $167.3M | $145.9M | $208.5M | $297.9M | $302.9M |
| Operating income | $192.2M | $164.2M | $188.8M | $264.5M | $328.7M | $375.9M | $383.3M | $186.3M |
| EBITDA | $211.5M | $200.0M | $246.2M | $314.1M | $397.6M | $445.8M | $253.5M | $288.9M |
| Net income | $163.5M | $121.1M | $129.2M | $216.1M | $292.5M | $325.3M | $263.2M | $222.4M |
| Net margin | 40.0% | 21.8% | 19.3% | 33.6% | 31.6% | 29.6% | 20.8% | 17.1% |
| EPS (diluted) | 0.04 | 0.03 | 0.03 | 0.05 | 0.06 | 0.07 | 0.06 | 0.05 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.5B | $0.08 | $0.08–$0.08 | 1 |
| 2027 | $1.7B | $0.11 | $0.11–$0.11 | 1 |
Forward consensus · source: Financial Modeling Prep
LIFETECH SCIENTIFIC CORP
No one on the platform currently holds LFTSF.
No tracked institution reports a position in LFTSF as of their last filing.
No one on the platform has traded LFTSF yet.
| $762M |
| — |
| PHCIPanamera Holdings Corporation | $2.50 | +0.00% | $185M | — |
| RKAGYRHON-KLINIKUM AG Unsponsored ADR | $8.16 | +0.00% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.